FrancophonIA/ELRC3.0 huggingface dataset:
English: Discontinue treatment and institute supportive care until resolution of all clinical signs of blood in stool, then decrease dose by 0.5 mg/kg
Croatian: Prekinuti terapiju i uvesti potpornu skrb do prestanka svih kliničkih simptoma krvi u stolici, zatim smanjivati dozu po 0,5 mg/kg
English: Palladia 50 mg tablets:
Croatian: Tablete Palladia od 50 mg:
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Palladia 10 mg film-coated tablets for Dogs
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Palladia 10 mg filmom obložena tableta za pse
English: Dose reductions and/or dose interruptions may be needed to manage adverse events.
Croatian: Za tretman nuspojava možda će biti potrebno smanjiti i/ili prekinuti dozu.
English: Treatment of non-resectable Patnaik grade II (intermediate grade) or III (high grade), recurrent, cutaneous mast cell tumours.
Croatian: Terapija neresektabilnog, rekurentnog, kutanog tumora mastocita drugog stupnja (srednji stupanj) ili trećeg (visokog stupnja) prema Patnaiku.
English: Palladia tablets should be given to your dog immediately after they are removed from the blister and should not be left around where they could be handled/swallowed by children.
Croatian: Tablete Palladia psu treba dati odmah nakon vađenja iz blistera.
English: Some very common (more than 1 in 10 animals treated displaying adverse reaction(s)) adverse reactions associated with Palladia tablets are weight loss, diarrhoea, neutropenia (low number of white blood cells), blood in faeces/ haemorrhagic diarrhoea/gastrointestinal bleeding, anorexia, lethargy, vomiting, lameness/ musculoskeletal disorder, dehydration, dermatitis, pruritus (skin irritation/scratching), increased alanine aminotransferase, thrombocytopenia, decreased albumin, decreased haematocrit.
Croatian: Neke vrlo česte nuspojave koje su se pojavile u više od 1 na 10 tretiranih pasa povezane s tabletama Palladia jesu gubitak težine, proljev, neutropenija (nizak broj leukocita), krv u stolici/krvavi proljev/gastrointestinalno krvarenje, anoreksija, letargija, povraćanje; hromost/mišićno-koštani poremećaj, dehidracija, dermatitis, svrbež (iritacija kože/grebanje); povišena alanin-aminotransferaza, trombocitopenija, sniženi albumin, sniženi hematokrit.
English: DOSING TABLE: PALLADIA TABLETS AT 3.25 MG/KG BODYWEIGHT
Croatian: TABELA ZA DOZIRANJE PALLADIA TABLETA U KOLIČINI OD 3,25 MG NA KILOGRAM TJELESNE TEŽINE
English: Do not use in pregnant or lactating bitches or in dogs intended for breeding.
Croatian: Ne davati kujama koje su skotne ili koje doje ili rasplodnim psima.
English: Another dog developed epistaxis with concurrent disseminated intravascular coagulopathy.
Croatian: U još se jednog psa se razvio epistaksis uz istovremenu diseminiranu intravaskularnu koagulopatiju.
English: • Vomiting, diarrhoea, anorexia, lethargy, dehydration, pyrexia, blood in faeces/haemorrhagic diarrhoea/gastrointestinal bleeding, duodenal ulceration, nausea, septicaemia, skin necrosis, weight loss; increased alanine aminotransferase, decreased haematocrit.
Croatian: • Povraćanje, proljev, anoreksija, letargija, dehidracija, vrućica, krv u stolici/krvavi proljev/gastrointestinalno krvarenje, duodenalna ulceracija, mučnina, septikemija, nekroza kože, gubitak težine; povišena alanin-aminotransferaza, snižen hematokrit.
English: • Blood urea nitrogen < 1.5x upper normal limit
Croatian: • Urea nitrat u krvi < 1 puta gornja normalna granica
English: Treatment should be permanently discontinued if severe adverse events recur or persist despite appropriate supportive care and dose reduction as described in the following table.
Croatian: Ako se teške nuspojave ponavljaju i ustraju usprkos odgovarajućoj potpornoj skrbi i smanjenju doze u skladu s tabelom u nastavku, terapiju treba trajno prekinuti.
English: 4.2 Indications for use, specifying the target species Treatment of non-resectable Patnaik grade II (intermediate grade) or III (high grade), recurrent, cutaneous mast cell tumours in dogs.
Croatian: Terapija neresektabilnog, rekurentnog, kutanog tumora mastocita drugog (srednji stupanj) ili trećeg stupnja (visokog stupnja) prema Patnaiku, kod pasa.
English: • Diarrhoea, neutropenia, weight loss, blood in faeces/hemorrhagic diarrhoea/gastrointestinal bleeding, anorexia, lethargy, vomiting; lameness / musculoskeletal disorder, dehydration, dermatitis, pruritus; increased alanine aminotransferase, thrombocytopenia, decreased albumin, decreased haematocrit.
Croatian: • Proljev, neutropenija, gubitak težine, krv u stolici/krvavi proljev/gastrointestinalno krvarenje, anoreksija, letargija, povraćanje; šepanje/mišićno-koštani poremećaj, dehidracija, dermatitis, svrbež; povišena alanin-aminotransferaza, trombocitopenija, sniženi albumin, sniženi hematokrit.
English: Keep children away from faeces, urine or vomit of treated dogs.
Croatian: Ne dopuštajte djeci kontakt s fekalijama, urinom ili povraćanim sadržajem liječenih pasa.
English: Black tarry stools
Croatian: Località Marino del Tronto
English: Discontinue treatment until >1.5 g/dl and clinical signs normal, then decrease dose by 0.5 mg/kg
Croatian: Prekinuti terapiju do > 1,5 g/dl i normalni klinički simptomi, zatim smanjivati dozu po 0,5 mg/kg
English: Palladia 50 mg film-coated tablets for Dogs
Croatian: Palladia 50 mg filmom obložena tableta za pse
English: Discontinue treatment until formed stools and institute supportive care, then decrease dose by 0.5 mg/kg
Croatian: Prekinuti terapiju do pojave formirane stolice i uvesti potpornu skrb, zatim smanjivati dozu po 0,5 mg/kg
English: Palladia 15 mg film-coated tablets for Dogs
Croatian: Palladia 15 mg filmom obložena tableta za pse
English: Discontinue treatment until >1000/µl and clinical signs normal, then decrease dose by 0.5 mg/kg
Croatian: Prekinuti terapiju do > 1000/µl i normalnih kliničkih simptoma, zatim smanjivati dozu po 0,5 mg/kg
English: Gastrointestinal discomfort such as vomiting or diarrhoea may occur if this drug is accidentally ingested.
Croatian: Ako se ovaj lijek nehotice proguta, može doći do gastrointestinalnih poteškoća kao što su povraćanje ili proljev.
English: toceranib
Croatian: NUSPOJAVE
English: Palladia 10 mg tablets for dogs.
Croatian: Palladia 10 mg tableta za pse Palladia 15 mg tableta za pse Palladia 50 mg tableta za pse toceranib
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Croatian: 15. IME I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET Zoetis Belgium SA
English: Lot
Croatian: ITALIJA
English: STATEMENT OF ACTIVE SUBSTANCES
Croatian: IZVJEŠĆE O MRL
English: Renal Toxicity (creatinine) <1.25 X upper normal limit
Croatian: Bubrežna toksičnost (kreatinin) < 1,25 puta gornja normalna granica Zadržati razinu doze ≥ 1,25 puta gornja normalna granica Prekinuti terapiju do < 1,25 puta gornja normalna granica,
English: METHOD AND ROUTE(S) OF ADMINISTRATION For oral use.
Croatian: NAČIN I PUTEVI PRIMJENE
English: Patient specific up to 50 ml max.
Croatian: Specifično za bolesnika, najviše do 50 ml
English: EU/1/18/1297/001 Kymriah
Croatian: EU/1/18/1297/001 Kymriah 1,2 x 1066 x 108 stanica
English: 1-3 bags
Croatian: 1-3 vrećice
English: Bag (ethylene vinyl acetate)
Croatian: Vrećica (etilenvinilacetat)
English: MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging
Croatian: Broj (EU) odobrenja (Zaštićeno) ime Doza Farmaceutski oblik Put primjene
English: Pack size
Croatian: Unutarnje pakovanje Veličina pakovanja
English: The full EPAR for Zarzio can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Zarzio nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Zarzio is used as safely as possible.
Croatian: Razvijen je plan upravljanja rizikom kako bi se osiguralo da se Zarzio koristi što je sigurnije moguće.
English: Four studies looked at the levels of neutrophils in the blood in a total of 146 healthy volunteers who received Zarzio or Neupogen.
Croatian: Četiri ispitivanja istražila su razine neutrofila u krvi 146 zdrava dobrovoljca koji su primali Zarzio ili Neupogen.
English: Zarzio is used to stimulate the production of white blood cells in the following situations:
Croatian: Zarzio se koristi za stimulaciju proizvodnje leukocita u sljedećim situacijama:
English: Why has Zarzio been approved?
Croatian: Zašto je Zarzio odobren?
English: What measures are being taken to ensure the safe and effective use of Zarzio?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Zarzio?
English: The European Commission granted a marketing authorisation valid throughout the EU for Zarzio on 06 February 2009.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Zarzio na snazi u Europskoj unijo od 6. veljače 2009.
English: Zarzio is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately.
Croatian: Zarzio se obično daje u specijaliziranim centrima za liječenje, ali bolesnici koji taj lijek primaju potkožnom injekcijom mogu ga ubrizgavati i sami po završetku odgovarajuće obuke.
English: Other side effects may be seen in more than 1 patient in 10, depending on the condition that Zarzio is being used for.
Croatian: Druge nuspojave mogu se javiti u više od 1 na 10 osoba, ovisno o stanju za koje se Zarzio primjenjuje.
English: Zarzio is a ‘biosimilar' medicine.
Croatian: Zarzio je „biosličan” lijek.
English: This is a summary of the European public assessment report (EPAR) for Zarzio.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Zarzio.
English: The most common side effect with Zarzio (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones).
Croatian: Najčešće nuspojave lijeka Zarzio (koje se mogu javiti u više od 1 na 10 osoba) su mišićno-koštana bol (bol u mišićima i kostima).
English: For more information about treatment with Zarzio, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Zarzio pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: The active substance in Zarzio, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G CSF).
Croatian: Djelatna tvar u lijeku Zarzio, filgrastim, vrlo je sličan ljudskom proteinu naziva čimbenik poticanja rasta granulocitnih kolonija (G-CSF).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zarzio.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek Zarzio kako bi donio mišljenje u korist davanja odobrenja za stavljanje u promet i preporučio uvjete za njegovu primjenu.
English: This means that Zarzio is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘reference medicine').
Croatian: Drugim riječima, Zarzio je sličan biološkom lijeku (poznatom kao „referentni lijek“) koji je već odobren u Europskoj uniji (EU) i sadrži istu djelatnu tvar.
English: Other information about Zarzio
Croatian: Ostale informacije o lijeku Zarzio
English: Therefore, the CHMP's view was that, as for Neupogen, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMP-a da, kao u slučaju lijeka Neupogen, koristi nadmašuju utvrđeni rizik.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zarzio, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana u sažetku opisa svojstava lijeka kao i u uputi o lijeku za Zarzio nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: What is the risk associated with Zarzio?
Croatian: Koji su rizici povezani s lijekom Zarzio?
English: What is Zarzio?
Croatian: Što je Zarzio?
English: The Committee recommended that Zarzio be given marketing authorisation.
Croatian: Odbor je preporučio da za lijek Zarzio odobri izdavanje odobrenja za stavljanje lijeka u promet.
English: Zarzio is given by injection under the skin or infusion into a vein.
Croatian: Zarzio se primjenjuje potkožnom injekcijom ili infuzijom u venu.
English: Zarzio and Neupogen brought about similar increases in blood neutrophil counts in healthy volunteers over the course of the studies.
Croatian: Lijekovi Zarzio i Neupogen rezultirali su otprilike sličnim povećanjem broja neutrofila u krvi dobrovoljaca tijekom tih ispitivanja.
English: How does Zarzio work?
Croatian: Kako djeluje Zarzio?
English: Zarzio was studied to show that it is comparable to the reference medicine, Neupogen.
Croatian: Zarzio se ispitivao radi dokazivanja njegove usporedivosti s referentnim lijekom, lijekom Neupogen.
English: The CHMP decided that, in accordance with EU requirements, Zarzio has been shown to have a comparable quality, safety and efficacy profile to Neupogen.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je kako je u skladu sa zahtjevima EU-a za bioslične lijekove dokazano da lijek Zarzio posjeduje usporedivu razinu kvalitete, sigurnosti i djelotvornosti kao i Neupogen.
English: Zarzio is a solution for injection or infusion (drip into a vein) in a pre-filled syringe.
Croatian: Zarzio je otopina za injekciju ili infuziju (drip u venu) kao prethodno napunjena šprica.
English: Zarzio can also be used in people who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Croatian: Zarzio se može koristiti i kao pomoć za otpuštanje stanica iz koštane srži kod ljudi koji će donirati matične stanice za transplantaciju.
English: This was considered sufficient to demonstrate that the benefits of Zarzio are comparable to those of the reference medicine.
Croatian: To se smatralo dostatnim dokazom da su koristi lijeka Zarzio usporedive s koristima referentnog lijeka.
English: What is Zarzio used for?
Croatian: Za što se Zarzio koristi?
English: The reference medicine for Zarzio is Neupogen.
Croatian: Neupogen je referentni lijek za Zarzio.
English: What benefit has Zarzio shown during the studies?
Croatian: Koje su koristi lijeka Zarzio utvrđene u ispitivanjima?
English: How is Zarzio used?
Croatian: Kako se Zarzio koristi?
English: Package size
Croatian: Put primjene Pakovanje Veličina pakovanja
English: It is available as capsules (5, 20, 100, 140, 180 and 250 mg).
Croatian: Dostupan je u obliku kapsula (5, 20, 100, 140,180 i 250 mg).
English: The dose of Temomedac depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day.
Croatian: Doza lijeka Temomedac ovisi o površini tijela (izračunata uporabom bolesnikove visine i težine) i kreće se u rasponu od 75 do 200 mg po metru kvadratnom, jednom na dan.
English: Temomedac capsules should be taken whole without food.
Croatian: Kapsule lijeka Temomedac treba uzimati cijele bez hrane.
English: Patients may also need to take medicines to prevent vomiting before taking Temomedac.
Croatian: Bolesnici također mogu imati potrebu uzimati lijekove za sprječavanje povraćanja prije nego uzmu Temomedac.
English: Temomedac is used first with radiotherapy and then on its own;
Croatian: Temomedac se prvo koristi s radioterapijom, a potom sam;
English: The full EPAR for Temomedac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku Temomedac (EPAR) može se naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: As a result, the cancer cells cannot divide, slowing down the growth of tumours.
Croatian: Kao rezultat toga stanice karcinoma ne mogu se dijeliti što usporava rast tumora.
English: • adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment.
Croatian: • odrasli i djeca u dobi od tri godine i starija s malignim gliomom poput multiformnog glioblastoma ili anaplastičnog astracitoma kad se tumor vratio ili pogoršao nakon standardnog liječenja.
English: The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temomedac is being used alone or with other treatments, and how the patient responds to treatment.
Croatian: Doza i broj doza ovisi o vrsti tumora koji se liječi, o tome da li je bolesnik prethodno liječen, da li se Temomedac koristi sam ili s drugim terapijama i o tome kako bolesnik reagira na liječenje.
English: This means that Temomedac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Temodal.
Croatian: To znači da je Temomedac sličan „referentnom lijeku“ koji je već odobren u Europskoj uniji (EU) pod nazivom Temodal.
English: Temomedac temozolomide
Croatian: Temomedac temozolomid
English: Temomedac is used to treat malignant glioma (brain tumours) in the following groups of patients:
Croatian: Temomedac se koristi za liječenje malignog glioma (tumora mozga) u sljedećim skupinama bolesnika:
English: What are the benefits and risks of Temomedac?
Croatian: Koje su koristi i rizici lijeka Temomedac?
English: Temomedac is a ‘generic medicine'.
Croatian: Temomedac je „generički lijek“.
English: Temomedac is used on its own in these patients.
Croatian: Temomedac se kod tih bolesnika koristi sam.
English: In the body, temozolomide is converted to another compound called MTIC.
Croatian: U tijelu se temozolomid pretvara u drugu tvar zvanu MTIC.
English: • adults with newly diagnosed glioblastoma multiforme (an aggressive type of brain tumour).
Croatian: • odrasli bolesnici s dijagnosticiranim multiformnim glioblastomom (agresivnim tipom tumora mozga).
English: MTIC binds to the DNA of cells while they are reproducing, which stops cell division.
Croatian: MTIC se veže na DNK stanica dok se razmnožavaju što zaustavlja njihovu diobu.
English: The European Commission granted a marketing authorisation valid throughout the EU for Temomedac on 25 January 2010.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Temomedac vrijedi na prostoru Europske unije od 25. siječnja 2010.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temomedac.
Croatian: Objašnjava kako je Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) ocijenilo lijek Temomedac da bi postiglo mišljenje u korist davanja odobrenja za stavljanje na tržište i preporučilo uvjete za njegovu primjenu.
English: Treatment with Temomedac should be prescribed by a doctor with experience in the treatment of brain tumours.
Croatian: Liječenje lijekom Temomedac treba započeti liječnik koji ima iskustva u liječenju tumora mozga.
English: Because Temomedac is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.
Croatian: Budući da je Temomedac generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: For more information about treatment with Temomedac, read the Package Leaflet (also part of the EPAR).
Croatian: Više informacija o liječenju lijekom Temomedac pročitajte u uputi o lijeku (također dio EPAR-a).
English: Other information about Temomedac:
Croatian: Druge informacije o lijeku Temodal:
English: This document is a summary of the European Public Assessment Report (EPAR) for Temomedac.
Croatian: Ovo je sažetak Europskog javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) Temomedac.
English: The active substance in Temomedac, temozolomide, belongs to a group of cancer medicines called alkylating agents.
Croatian: Djelatna tvar u lijeku Temomedac, temozolomid pripada skupini lijekova protiv karcinoma zvanih alkilirajući agensi.
English: The Committee recommended that Temomedac be given marketing authorisation.
Croatian: Povjerenstvo je preporučilo izdavanje odobrenja za stavljanje u promet lijeka Temomedac.
English: Temomedac is a cancer medicine that contains the active substance temozolomide.
Croatian: Temomedac je lijek protiv karcinoma koji sadrži djelatnu tvar temozolomid.
English: What is Temomedac?
Croatian: Što je Temomedac?
English: Because Temomedac is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal.
Croatian: Budući da je Temomedac generički lijek, ispitivanja su na bolesnicima bila ograničena na ispitivanja za utvrđivanje je li lijek bioekvivalentan referentnom lijeku Temodal.
English: How has Temomedac been studied?
Croatian: Kako je Temomedac proučavan?
English: For full details, see the summary of product characteristics (also part of the EPAR).
Croatian: Za više informacija pogledajte Sažetak opisa svojstava lijeka (koji je također dio EPAR-a).
English: Why has Temomedac been approved?
Croatian: Zašto je lijek Temomedac odobren?
English: The CHMP concluded that, in accordance with EU requirements, Temomedac has been shown to have comparable quality and to be bioequivalent to Temodal.
Croatian: Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) pri Agenciji zaključilo je kako, u skladu s preduvjetima EU-a, lijek Temomedac posjeduje usporedivu kvalitetu te je bioekvivalentan s lijekom Temodal.
English: What is Temomedac used for?
Croatian: Za što se Temomedac koristi?
English: Therefore, the CHMP's view was that, as for Temodal, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMP-a kako koristi nadmašuju utvrđene rizike, kao i kod lijeka Temodal.
English: How is Temomedac used?
Croatian: Kako se Temomedac koristi?
English: How does Temomedac work?
Croatian: Kako djeluje Temomedac?
English: 1 vial + 1 filter needle
Croatian: 1 bočica + 1 igla s filterom
English: Strength Pharmaceutical form
Croatian: Jačina Farmaceutski oblik Put primjene Unutarnje pakiranje
English: It has no relevant use in patients under 18 years of age.
Croatian: Nema relevantnu primjenu u bolesnika mlađih od 18 godina.
English: Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba
Croatian: Epilobium angustifolium L. i/ili Epilobium parviflorum Schreb., herba
English: BPH is a non-cancerous increase in size of the prostate gland which surrounds the urethra, the tube that carries urine from the bladder out of the body.
Croatian: BPH je nekancerogeno povećanje prostate, koja okružuje uretru, cijev kojom prolazi urin iz mjehura izvan tijela.
English: 2 February 2016 EMA/822538/2015
Croatian: EMA/822538/2015
English: Willow herb EMA/822538/2015
Croatian: Zelen vrbolike EMA/822538/2015
English: Willow herb preparations are obtained by drying and comminuting (reducing into tiny pieces) the aerial parts of the plant.
Croatian: Pripravci od zeleni vrbolike dobivaju se sušenjem i usitnjavanjem (smanjivanjem na manje komadiće) nadzemnih dijelova biljke.
English: Willow herb should only be used after serious conditions have been excluded by a medical doctor.
Croatian: Zelen vrbolike smije se koristiti samo nakon što je liječnik isključio ozbiljna stanja.